$VINC
Vincerx Pharma, Inc.

2020 Q3 Form 10-Q Financial Statement

#000156459020052823 Filed on November 10, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2020 Q2 2019 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $440.4K $130.0K $100.00
YoY Change 440286.0%
Operating Profit -$440.4K -$100.00
YoY Change 440286.0%
Interest Expense $10.00K $30.00K
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$430.0K -$110.0K
YoY Change
Income Tax $0.00
% Of Pretax Income
Net Earnings -$434.3K -$110.0K -$100.00
YoY Change 434204.0%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$262.2K -$67.07K
COMMON SHARES
Basic Shares Outstanding 8.205M 8.205M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2020 Q2 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $560.0K $680.0K
YoY Change
Cash & Equivalents $562.8K $684.7K $25.00K
Short-Term Investments
Other Short-Term Assets $70.00K $110.0K
YoY Change
Inventory
Prepaid Expenses $106.3K
Receivables
Other Receivables
Total Short-Term Assets $640.0K $791.0K
YoY Change 3064.16%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $65.70M $65.69M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $65.69M $65.69M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $640.0K $791.0K
Total Long-Term Assets $65.69M $65.69M
Total Assets $66.33M $66.48M
YoY Change 265831.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $400.0K $120.0K
YoY Change
Accrued Expenses $115.5K
YoY Change 7862.21%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $400.0K $116.3K
YoY Change 7918.21%
LONG-TERM LIABILITIES
Long-Term Debt $1.000M $1.000M
YoY Change
Other Long-Term Liabilities $2.300M $2.300M
YoY Change
Total Long-Term Liabilities $3.300M $3.300M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $400.0K $116.3K
Total Long-Term Liabilities $3.300M $3.300M
Total Liabilities $3.700M $3.414M
YoY Change 235319.52%
SHAREHOLDERS EQUITY
Retained Earnings -$555.3K -$121.0K
YoY Change 8244.28%
Common Stock $244.00 $240.00
YoY Change 66.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.000M $5.000M $23.45K
YoY Change
Total Liabilities & Shareholders Equity $66.33M $66.48M
YoY Change 265831.91%

Cashflow Statement

Concept 2020 Q3 2020 Q2 2019 Q3
OPERATING ACTIVITIES
Net Income -$434.3K -$110.0K -$100.00
YoY Change 434204.0%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$121.9K -$70.00K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -121.9K -70.00K
Cash From Investing Activities 0.000
Cash From Financing Activities 0.000
Net Change In Cash -121.9K -70.00K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$121.9K -$70.00K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q2 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
1000000
CY2020Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
106333
CY2020Q2 us-gaap Assets Current
AssetsCurrent
791041
CY2020Q3 us-gaap Long Term Investments
LongTermInvestments
65698018
CY2020Q2 us-gaap Long Term Investments
LongTermInvestments
65691936
CY2020Q3 us-gaap Assets
Assets
66334714
CY2020Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
401493
CY2020Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
115452
CY2020Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
812
CY2020Q3 lsacu Deferred Underwriting Fee Payable
DeferredUnderwritingFeePayable
2297319
CY2020Q2 lsacu Deferred Underwriting Fee Payable
DeferredUnderwritingFeePayable
2297319
CY2020Q3 us-gaap Liabilities
Liabilities
3699624
CY2020Q2 us-gaap Liabilities
Liabilities
3413583
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
57635080
CY2020Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
58069390
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
244
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
240
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
5555062
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
5120756
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-555296
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-120992
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
5000010
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
5000004
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
66334714
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
66482977
CY2020Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
5763508
CY2020Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
5806939
CY2020Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
10.00
CY2020Q2 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
10.00
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2441201
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2397770
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
440386
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
100
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-440386
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2441201
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2397770
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-100
CY2020Q3 us-gaap Investment Income Net
InvestmentIncomeNet
6082
CY2020Q3 us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
434310
CY2019Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
100
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
23550
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
23450
CY2020Q3 lsacu Stock Issued During Period Shares Share Based Compensation Forfeited Outstanding
StockIssuedDuringPeriodSharesShareBasedCompensationForfeitedOutstanding
225000
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-434304
CY2019Q3 us-gaap Profit Loss
ProfitLoss
-100
CY2020Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-32420
CY2020Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
286041
CY2020Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-121925
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-121925
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
684708
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
562783
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25000
CY2020Q3 lsacu Noncash Or Part Noncash Change In Value Of Common Stock Subject To Possible Redemption
NoncashOrPartNoncashChangeInValueOfCommonStockSubjectToPossibleRedemption
-434310
CY2020Q3 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p>
CY2020Q1 lsacu Underwriter Cash Discount Per Share
UnderwriterCashDiscountPerShare
0.20
CY2020Q3 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account with a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. At September 30, 2020 and June 30, 2020, the Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p>
CY2020Q1 lsacu Aggregate Cash Discount For Underwriter
AggregateCashDiscountForUnderwriter
1312753
CY2020Q3 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-12-19
CY2020Q1 us-gaap Common Stock Held In Trust
CommonStockHeldInTrust
60000000
CY2020Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
10.00
CY2020Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3757284
CY2020Q3 lsacu Payment Of Underwriter Fees
PaymentOfUnderwriterFees
1062753
CY2020Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
2297319
CY2020Q3 lsacu Payment Of Other Offering Costs
PaymentOfOtherOfferingCosts
397212
CY2020Q3 us-gaap Business Acquisition Share Price
BusinessAcquisitionSharePrice
10.00
CY2020Q3 lsacu Net Tangible Asset After Business Combination
NetTangibleAssetAfterBusinessCombination
5000001
CY2020Q3 us-gaap Business Acquisition Effective Date Of Acquisition1
BusinessAcquisitionEffectiveDateOfAcquisition1
2022-03-10
CY2020Q3 lsacu Percentage Of Outstanding Public Shares Redeemed
PercentageOfOutstandingPublicSharesRedeemed
1.00
CY2020Q3 lsacu Redemption Price Per Share
RedemptionPricePerShare
10.00
CY2020Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2020Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2020Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q3 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2020Q2 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2019Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
225000
CY2020Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
5851883
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
6082
CY2020Q3 us-gaap Income Taxes Paid
IncomeTaxesPaid
6082
CY2020Q3 us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
0
CY2020Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2020Q1 lsacu Number Of Demands Of Registration Rights
NumberOfDemandsOfRegistrationRights
2
CY2020Q1 lsacu Number Of Demand Registration Rights At Expense
NumberOfDemandRegistrationRightsAtExpense
1
CY2020Q1 lsacu Demand Registration Rights Exercise Period
DemandRegistrationRightsExercisePeriod
P5Y
CY2020Q1 lsacu Piggy Back Registration Rights Exercise Period
PiggyBackRegistrationRightsExercisePeriod
P7Y
CY2020Q1 lsacu Underwriter Deferred Fee Per Unit
UnderwriterDeferredFeePerUnit
0.35
CY2020Q1 lsacu Underwriter Deferred Fee
UnderwriterDeferredFee
2297319
CY2020Q3 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Holders of the Company’s common stock are entitled to one vote for each share.
CY2020Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
5763508
CY2020Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
5806939
CY2020Q3 lsacu Warrant Expiration Term
WarrantExpirationTerm
P5Y
CY2020Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01

Files In Submission

Name View Source Status
0001564590-20-052823-index-headers.html Edgar Link pending
0001564590-20-052823-index.html Edgar Link pending
0001564590-20-052823.txt Edgar Link pending
0001564590-20-052823-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
lsacu-10q_20200930.htm Edgar Link pending
lsacu-20200930.xml Edgar Link completed
lsacu-20200930.xsd Edgar Link pending
lsacu-20200930_cal.xml Edgar Link unprocessable
lsacu-20200930_def.xml Edgar Link unprocessable
lsacu-20200930_lab.xml Edgar Link unprocessable
lsacu-20200930_pre.xml Edgar Link unprocessable
lsacu-ex311_9.htm Edgar Link pending
lsacu-ex312_8.htm Edgar Link pending
lsacu-ex321_7.htm Edgar Link pending
lsacu-ex322_6.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending